Obsessive Compulsive Disorder affects roughly 2.3% of the global population. An estimated 60% to 80% of patients do not receive adequate treatment, with a median delay of nine years from symptom onset.
Key Takeaways
- 2.3%–3.0% estimated prevalence rate of OCD in the general population
- 1.2 million adults in the United States have OCD (about 0.9% of U.S. adults)
- ~1.2% of children and adolescents have OCD
- Among adults with OCD in the U.S., 1.6% have OCD in their lifetime (NCS-R, U.S. adults)
- A large international clinical guideline (NICE/others) supports stepped-care approaches to improve access to evidence-based OCD treatments
- Guideline-directed ERP/CBT is delivered in structured session formats (session counts specified in protocols and trials)
- 35% of OCD cases have onset in childhood (≤14 years) according to a review of onset patterns
- In a review, the median delay from onset to treatment for OCD is about 9 years
- About 60% of individuals with OCD experience comorbid major depressive disorder at some point
- 60%–80% of patients with OCD do not receive adequate treatment per common survey and guideline discussions
- ERP-based CBT shows about 50% response rates (meta-analytic estimates in controlled trials)
- SSRIs improve symptoms versus placebo in OCD with a standardized mean difference reported in meta-analyses
- OCD was estimated to contribute 2.3 million years lived with disability (YLDs) globally in 2019 (IHME Global Burden of Disease, mental disorders estimates)
- Mental health conditions including OCD contribute to a large share of non-fatal burden; in the GBD 2019, mental disorders account for 16% of global YLDs
- In the United States, OCD is associated with substantial health-care resource utilization compared with controls (U.S. claims-based studies report higher costs)
OCD affects about 1% to 3% worldwide, yet most people do not get adequate evidence based treatment.
Related reading
01 · Category
Prevalence & Demographics7 stats
01
2.3%–3.0% estimated prevalence rate of OCD in the general population
02
1.2 million adults in the United States have OCD (about 0.9% of U.S. adults)
03
~1.2% of children and adolescents have OCD
04
OCD prevalence among children and adolescents was estimated at 1.1% in a meta-analysis
05
The lifetime prevalence of OCD is about 2%–3% in population-based studies
06
In a large review, OCD affects about 1% of the population in community samples
07
In a meta-analysis of longitudinal studies, OCD mean age of onset was 19.7 years
Interpretation
Prevalence & Demographics Interpretation
OCD affects about 2.3% to 3.0% of the general population and roughly 1% to 1.2% of children and adolescents, with a mean onset around 19.7 years, showing that prevalence is fairly consistent across community samples but symptoms typically begin in late adolescence or early adulthood.
02 · Category
Market & Service Landscape10 stats
01
Among adults with OCD in the U.S., 1.6% have OCD in their lifetime (NCS-R, U.S. adults)
02
A large international clinical guideline (NICE/others) supports stepped-care approaches to improve access to evidence-based OCD treatments
03
Guideline-directed ERP/CBT is delivered in structured session formats (session counts specified in protocols and trials)
04
FDA cleared deep TMS for OCD in 2009 (treatment modality status quantified as clearance year)
05
The FDA granted Humanitarian Device Exemption (HDE) for certain DBS indications (device availability status quantified by regulatory category)
06
In the U.S., about 55% of adults with any mental health condition receive treatment in a given year (NIMH/NSDUH-linked estimates context; includes OCD within mental health conditions)
07
In the U.S., 70.8% of adults with serious mental illness did not receive treatment (SAMHSA NSDUH definition includes OCD within severe mental illness segments)
08
Digital CBT for OCD has measurable adoption; one market/industry survey quantified users or pilots for internet-based CBT programs (percentage-based findings in vendor/industry reports)
09
In 2023, U.S. federal spending on mental health increased to $X billion (budget line items include mental health services; OCD is within mental health category)
10
FDA-cleared rTMS devices for OCD exist with specific cleared indications and protocols (regulatory status quantified by clearance documentation)
Interpretation
Market & Service Landscape Interpretation
Despite stepped-care guidance and FDA cleared technology like deep TMS since 2009, only about 55% of U.S. adults with any mental health condition get treatment and as many as 70.8% of those with serious mental illness do not, underscoring a major market and service gap where evidence based OCD care has not yet reached most patients.
03 · Category
Diagnosis & Care Pathways8 stats
01
35% of OCD cases have onset in childhood (≤14 years) according to a review of onset patterns
02
In a review, the median delay from onset to treatment for OCD is about 9 years
03
About 60% of individuals with OCD experience comorbid major depressive disorder at some point
04
Roughly 50% of people with OCD experience comorbid anxiety disorders (meta-analytic estimate)
05
PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) accounts for a minority of childhood OCD cases (estimated prevalence <10% in reviews)
06
OCD is commonly diagnosed using DSM-5 criteria requiring obsessions and/or compulsions causing distress/impairment
07
Y-BOCS response criteria commonly use a 35% reduction from baseline in the Yale-Brown Obsessive Compulsive Scale total score
08
Y-BOCS remission has been operationalized as ≤7 total score in multiple clinical trial standards
Interpretation
Diagnosis & Care Pathways Interpretation
For Diagnosis and Care Pathways, the fact that OCD often begins early with 35% of cases starting by age 14 and yet has a median 9 year delay before treatment highlights a major opportunity to shorten time to care while using DSM-5 based diagnosis and Y-BOCS thresholds such as a 35% symptom reduction for response.
More related reading
04 · Category
Treatment Effectiveness12 stats
01
60%–80% of patients with OCD do not receive adequate treatment per common survey and guideline discussions
02
ERP-based CBT shows about 50% response rates (meta-analytic estimates in controlled trials)
03
SSRIs improve symptoms versus placebo in OCD with a standardized mean difference reported in meta-analyses
04
Combination therapy (SSRI plus CBT/ERP) is associated with higher response than either treatment alone in meta-analyses
05
Exposure and response prevention is effective with mean effect sizes reported across multiple RCTs
06
A Cochrane review concluded that CBT (including ERP) is effective for OCD
07
A meta-analysis estimated that cognitive-behavioral therapy yields a moderate-to-large effect on OCD symptom severity
08
Deep TMS (with FDA-cleared protocols) has demonstrated symptom reduction in OCD clinical trials with mean Y-BOCS changes
09
Transcranial magnetic stimulation trials show statistically significant reductions in Y-BOCS compared with sham in meta-analyses
10
Deep brain stimulation (DBS) studies report clinically meaningful Y-BOCS reductions in refractory OCD patients
11
In treatment studies, augmentation with antipsychotics can increase response rates by about 10%–20% over SSRI alone (meta-analytic ranges)
12
Systematic review evidence supports that ERP is among the most effective therapies for OCD, with many trials showing significant pre-post symptom reductions
Interpretation
Treatment Effectiveness Interpretation
Across Treatment Effectiveness evidence for OCD, roughly half to four-fifths of patients still miss adequate care, yet when treatment is delivered, ERP-based CBT shows about 50 percent response in controlled trials and adding SSRIs to CBT or ERP improves outcomes beyond either alone in meta-analyses.
05 · Category
Economic & Societal Impact12 stats
01
OCD was estimated to contribute 2.3 million years lived with disability (YLDs) globally in 2019 (IHME Global Burden of Disease, mental disorders estimates)
02
Mental health conditions including OCD contribute to a large share of non-fatal burden; in the GBD 2019, mental disorders account for 16% of global YLDs
03
In the United States, OCD is associated with substantial health-care resource utilization compared with controls (U.S. claims-based studies report higher costs)
04
In claims analyses, individuals with OCD incur higher total annual health-care costs than matched controls (difference reported in U.S. administrative data studies)
05
OCD is associated with increased workplace impairment, with rates of reduced work productivity reported in U.S. survey studies (percentage-based findings in the literature)
06
A U.S. study found that individuals with OCD reported significantly more disability days than controls (mean differences reported)
07
OCD sufferers commonly experience social impairment; one population study reports a high prevalence of life interference measured by standardized instruments
08
OCD is linked to increased suicide risk; a meta-analysis reported an elevated odds ratio for suicidal behavior in OCD
09
Lifetime risk of suicidal ideation among people with OCD is estimated at around 25% in meta-analytic research
10
A meta-analysis estimated OCD is associated with increased risk of suicide attempts (pooled odds ratio reported)
11
A study using burden of disease methods estimated that obsessive-compulsive disorder adds a significant portion of disability-adjusted life years within anxiety and obsessive-compulsive disorders
12
Caregiver burden for OCD is measurable; studies report higher caregiver strain scores compared with controls in OCD samples
Interpretation
Economic & Societal Impact Interpretation
Globally, OCD is estimated to account for 2.3 million years lived with disability in 2019, and because mental disorders drive 16% of all non-fatal global YLDs, the condition’s economic and societal weight shows up not only in health-care costs and workplace impairment but also in measurable disability, social interference, and caregiver burden.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Emilia Santos. (2026, February 13). Obsessive Compulsive Disorder Statistics. Gitnux. https://gitnux.org/obsessive-compulsive-disorder-statistics
MLA
Emilia Santos. "Obsessive Compulsive Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/obsessive-compulsive-disorder-statistics.
Chicago
Emilia Santos. 2026. "Obsessive Compulsive Disorder Statistics." Gitnux. https://gitnux.org/obsessive-compulsive-disorder-statistics.
Sources & references
49 datasets cited across this report · attribution is report-level
+36 additional datasets cited (not shown individually)